Inventor · disambiguated record
Franziska Hoffgaard
Also filed as: HOFFGAARD FRANZISKA
76 granted patents·27 pending applications·29 citations·filing 2017–2025
99Inventor score
Files withIMMATICS BIOTECHNOLOGIES GMBH103
Top patents by PatentIndex Score
103 records- 0198US10772915B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Sep 15, 2020·5 cites·20 claims
- 0298US10695374B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·5 cites·26 claims
- 0397US11208449B2Peptides for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Dec 28, 2021·3 cites·20 claims
- 0497US10709738B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 14, 2020·3 cites·20 claims
- 0595US11072645B2T cell receptors with improved pairingIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Jul 27, 2021·10 cites·5 claims
- 0695US11020433B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jun 1, 2021·2 cites·20 claims
- 0791US2023285461A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 0891US2023285462A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 0990US2023241109A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1090US2023241112A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1190US2023241113A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1290US2023285460A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1390US2023241110A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1490US2023233612A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1590US2023241108A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1690US2023241114A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1790US2023241115A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1890US2023263830A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 1989US10709736B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jul 14, 2020·0 cites·35 claims
- 2089US10702553B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jul 7, 2020·0 cites·25 claims
- 2189US10695376B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·0 cites·25 claims
- 2289US10695377B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·0 cites·27 claims
- 2389US10695375B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·0 cites·22 claims
- 2489US2024075119A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2588US11969464B2Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Granted Apr 30, 2024·0 cites·20 claims
- 2688US10695373B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·0 cites·25 claims
- 2788US2024016910A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2888US2024016912A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2988US2024024441A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3088US2024016913A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3188US2024016906A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3288US2024024440A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3388US2024016907A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3488US2023414734A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3588US2024016909A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3688US2024016911A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3788US2024075118A1Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3887US11904003B2Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Granted Feb 20, 2024·0 cites·20 claims
- 3987US11214604B2Peptides for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jan 4, 2022·1 cites·20 claims
- 4087US2024425558A1Peptides for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4186US12060400B2Peptides for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Granted Aug 13, 2024·0 cites·21 claims
- 4286US11077142B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Aug 3, 2021·0 cites·20 claims
- 4386US11033583B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 15, 2021·0 cites·20 claims
- 4486US10993962B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted May 4, 2021·0 cites·12 claims
- 4586US10894064B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jan 19, 2021·0 cites·20 claims
- 4685US11369636B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 28, 2022·0 cites·20 claims
- 4785US11357797B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jun 14, 2022·0 cites·20 claims
- 4884US11951132B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Apr 9, 2024·0 cites·20 claims
- 4984US11918607B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 5, 2024·0 cites·20 claims
- 5084US11376281B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jul 5, 2022·0 cites·20 claims
Showing the top 50 of 103 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Franziska Hoffgaard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →